Guatemala

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Merck Mectizan Donation Program

Onchocerciasis, or river blindness, is a leading cause of infectious blindness in the developing world. The Merck Mectizan Donation Program (MDP) was launched in 1987, when Merck & Co., Inc. announced that it would donate Mectizan (ivermectin), for the treatment of onchocerciasis to all who needed it for as long as needed.

Leprosy Elimination

Novartis is providing free treatment for leprosy patients worldwide through its multi-drug therapy.

Bayer HealthCare: Fight Against Chagas Disease

In April 2007, Bayer signed a new agreement to provide the World Health Organization (WHO) with 2.5 million Lampit tablets and additional funding for the distribution of the drug. The latest agreement assures the supply of Lampit until 2012. To widen access of patients to affordable medicines, Bayer HealthCare signed agreements with the World Health Organization (WHO) in 2004 and 2005 for donations of its medicine Lampit (nifurtimox) to combat Chagas disease, the form of sleeping sickness found in Latin America.

World Bank

The World Bank is a vital source of financial and technical assistance to developing countries around the world.

Pages